A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Antigen Dose-Escalation and Adjuvant Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Curevo Inc1 site in 1 country90 target enrollmentJanuary 3, 2019

ConditionsHerpes Zoster Varicella Zoster

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Herpes Zoster
Sponsor: Curevo Inc
Enrollment: 90
Locations: 1
Primary Endpoint: The number of subjects experiencing solicited local injection site reactions within 7 days following each study injection.
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

Registry

clinicaltrials.gov

Start Date

January 3, 2019

End Date

April 30, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Curevo Inc

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Males and non-pregnant females ≥ 18 to \< 50 years of age at the time of enrollment.
•In good general health as confirmed by a medical history and physical exam, vital signs\*, and screening laboratories conducted no more than 30 days prior to study injection administration.
•\*Oral Temperature \<38°C, respiratory rate \< 17 breaths pm, heart rate ≤100 bpm and \>54 bpm, systolic blood pressure ≤150 mmHg and \>89 mmHg, diastolic blood pressure ≤95 mmHg.
•NOTE: Athletically trained subjects with a heart rate ≥40 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator and reasoning must be documented.
•Screening laboratory values must be within normal range or not clinically significant as determined by the PI and approved by the Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, random glucose, WBC with differential, hemoglobin, and platelet count.
•Negative HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
•Normal urinalysis or if abnormal determined to be not clinically significant by the PI and the Medical Monitor (trace protein is acceptable without medical monitor approval).
•Urine test result for recreational drugs/drugs of abuse that in the opinion of the PI would not be a concern for subject's safety, or ability to reliably attend visits, and perform required protocol procedures. If urine drug test is positive, reasoning for inclusion must be documented.
•Females of childbearing potential\* must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study vaccination (prior to vaccination), must not be breast-feeding, and women in sexual relationships with men must agree to practice acceptable contraception\*\* for the 30-day period before Day 0 through 90 days after the last study injection. These precautions are necessary due to unknown effects that CRV-101 might cause in a fetus or newborn infant.
•\*Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy or successful Essure® placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or \< 1 year of the last menses if menopausal). Post-menopausal defined as at least 12 months spontaneous amenorrhea and confirmed with FSH \> 40 mIU/ml.

Exclusion Criteria

•History of chickenpox or herpes zoster in the past 3 years.
•Immunization with a vaccine against herpes zoster (Zostavax® or Shingrix®).
•Participation in another experimental protocol with last receipt of any device, vaccine, or other immunomodulator investigational products within the past 180 days of enrollment, or last receipt of non-device, non-vaccine, non-immunomodulator investigational products with in the last 90 days of enrollment or 5 half-lives whichever is greater, or planned participation in any other investigational study during the study period.
•Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs (e.g. oral or injected steroids, such as prednisone; high dose inhaled steroids; biologics (e.g. TNF inhibitor, or other cytokine inhibitors) or cytotoxic therapies, such as chemotherapy drugs or radiation) within 180 days prior to enrollment and during the study through Day 365 visit. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Low dose inhaled and topical steroids are allowed.
•Received a blood transfusion or immunoglobulin within past 90 days of enrollment.
•Donated blood products (platelets, whole blood, plasma, etc.) within past 60 days of enrollment.
•Received any vaccine within past 30 days prior to enrollment and no planned immunizations while on study with the exception of seasonal influenza vaccine which must not be given until 30 days after the last study injection and the Day 84 immunology blood has been drawn and a 30 day window prior to each immunology blood draw (Day 196, 365).
•History of autoimmune disease or other causes of immunosuppressive states.
•History of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
•Rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.

Outcomes

Primary Outcomes

The number of subjects experiencing solicited local injection site reactions within 7 days following each study injection.

Time Frame: 7 Days

The number of subjects spontaneously reporting unsolicited adverse events from Day 0 through 28 days after the last injection.

Time Frame: 28 Days

The number of medically-attended adverse events considered related to any of the study injections reported at any point during the study period events and potential immune-mediated medical conditions considered related to any of the study injections

Time Frame: 421 Days

The number of subjects experiencing solicited systemic reactions within 7 days following each study injection.

Time Frame: 7 Days

Secondary Outcomes

The frequencies of vaccine protein-specific T cells elicited by the CRV101 study vaccine at specified time points.(Day 0, 7, 28, 56, 63, 84, 196, and 365)
The levels of vaccine protein-specific antibodies elicited by the CRV101 study vaccine at specified time points(Day 0, 7, 28, 56, 63, 84, 196, and 365)